Patrick Gunning, Janpix founder and CSO (Gunning Group)
Medicxi splashes more funding into Janpix's STAT protein degrader program
Three years after giving University of Toronto professor Patrick Gunning a $19 million launch round to start Janpix, Medicxi is reaching deeper into its pockets to nudge the biotech’s first STAT protein degrader into the clinic.
On Wednesday, Cambridge, MA-based Janpix announced the closing of a modest $10 million Series B led by Medicxi. Roman Fleck — CEO and Medicxi venture advisor — says the funding will see the company’s first candidate to human testing, and expand its pipeline of STAT3 and STAT5 protein degraders.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
